News The curious case of Mylotarg: Pfizer's leukaemia drug set to... Mylotarg backed by advisers after withdrawal in 2010.
News Seattle Genetics leukaemia trial on hold after 4 deaths FDA concerned over potential liver toxicity.
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
